Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a strong-buy rating in a report released on Monday morning.

A number of other research firms have also weighed in on ALNY. Royal Bank Of Canada upped their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. UBS Group upped their price objective on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price objective on the stock. Jefferies Financial Group reduced their target price on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $482.17.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $452.74 on Monday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a market capitalization of $59.81 billion, a P/E ratio of -183.30 and a beta of 0.30. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $495.55. The company’s 50-day moving average is $458.85 and its 200 day moving average is $381.24.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $943.37 million. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. The company’s quarterly revenue was up 149.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the transaction, the executive vice president owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the sale, the director owned 16,804 shares of the company’s stock, valued at $7,561,800. The trade was a 40.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 66,696 shares of company stock worth $30,430,694 over the last ninety days. 1.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALNY. Consolidated Portfolio Review Corp purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at about $274,000. Crossmark Global Holdings Inc. boosted its position in Alnylam Pharmaceuticals by 17.2% in the third quarter. Crossmark Global Holdings Inc. now owns 1,224 shares of the biopharmaceutical company’s stock valued at $558,000 after buying an additional 180 shares during the last quarter. Orion Porfolio Solutions LLC increased its holdings in Alnylam Pharmaceuticals by 25.3% in the 3rd quarter. Orion Porfolio Solutions LLC now owns 5,398 shares of the biopharmaceutical company’s stock worth $2,461,000 after buying an additional 1,089 shares during the period. Insigneo Advisory Services LLC purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $205,000. Finally, Victory Capital Management Inc. raised its position in Alnylam Pharmaceuticals by 15.4% during the 3rd quarter. Victory Capital Management Inc. now owns 180,349 shares of the biopharmaceutical company’s stock worth $82,239,000 after buying an additional 24,055 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.